

Supplementary Table 5 Univariable and Multivariate analysis for OS according to Siglec-9+TAMs in Fudan Cohort.

Variables	Univariate			Multivariate		
	P value	HR	95%CI	P value	HR	95%CI
High-expressed Siglec-9 ligand						
Age	≥60 vs. <60	0.409	1.33	0.68-2.6		
FIGO staging	III-IV vs. I-II	0.012	4.60	1.4-15	0.037	3.74 1.08 - 12.91
Lymph node invasion	Yes vs. No	0.008	2.52	1.3-5	0.034	2.24 1.06 - 4.73
Tumor residual	>10mm vs. ≤10mm	0.160	1.68	0.82-3.5		
PD-L1	Positive vs. Negative	0.013	0.33	0.13-0.79	0.006	0.28 0.11 - 0.69
Siglec-9+TAMs	High vs. Low	0.047	2.01	1-4	0.049	2.01 1.00 - 4.02
CD68	High vs. Low	0.900	1.07	0.38 - 3.03		
CD163	High vs. Low	0.033	2.29	1.07 - 4.89		
Low-expressed Siglec-9 ligand						
Age	≥60 vs. <60	0.064	2.03	0.96-4.3	0.235	1.58 0.74 - 3.38
FIGO staging	III-IV vs. I-II	0.032	4.84	1.1-20	0.058	4.12 0.95 - 17.88
Lymph node invasion	Yes vs. No	0.746	1.17	0.45-3.1		
Tumor residual	>10mm vs. ≤10mm	0.351	1.50	0.64-3.5		
PD-L1	Positive vs. Negative	0.210	0.60	0.27-1.3		
Siglec-9+TAMs	High vs. Low	0.447	1.33	0.64-2.8		
CD68	High vs. Low	0.156	1.81	0.80 - 4.13		
CD163	High vs. Low	0.396	1.39	0.65-2.95		

Abbreviations: HR, Hazard ratio; 95% CI, 95% Confidence intervals.

Abbreviation: HR, Hazard Ratio; CI: confidence interval

*Multivariate Cox regression analysis beyond risk score.

Statistically significant data were marked with bold and underline.